Biotech – the red-hot, high risk investment story

The golden age of television

Matthew Partridge picks the stocks to watch

Biotech - the red-hot, high risk investment story

Biotech stocks have been booming over the last few years. Anyone who has invested will have made some very respectable profits. And it's a bull market that's set to continue for some time yet.

Invest in cutting-edge healthcare

Max King looks at one fund allowing investors to put their money in cutting-edge medical research.

The pharma price-gouging scandal

Pharmaceutical companies have hit the headlines for hiking prices for life-saving drugs by shocking amounts. What’s going on? Simon Wilson reports.

Three promising sectors for 2017

Max King tips a host of funds in various sectors to do well in the forthcoming year.

Lilly fails Alzheimer’s test

Eli Lilly’s new treatment has proved ineffective in late-stage trials – yet another blow for a struggling sector, says Ben Judge.

Who will prosper under Trump?

Now that the markets have got over the shock of a Trump victory in the US presidential election, David C Stevenson looks at which funds to buy.

Earn a 3.5% yield from healthcare

David C Stevenson looks at the best healthcare and biotech investment trusts to tuck away in your portfolio.

Novo Nordisk: Pharma giant takes a tumble

Novo Nordisk shocked investors by slashing its growth forecasts. The new CEO faces a tough start, says Ben Judge.

How we can profit from winning the battle against ageing

We’re now living longer than ever – only to suffer from diseases of old age. New therapies promise a new lease of life for the elderly – and big profits for investors, says Matthew Partridge.

Three long-term investment ideas for the brave

Professional investor Rebecca O’Keeffe looks at three long-term investment ideas – biotech, Indian equities, and smaller companies – and picks the best ways to invest in each.

Four promising biotech stocks to buy now

The recent correction in biotech stocks was overdone, says professional investor Dr Daniel Koller. Here, he picks four biotech companies to buy now.

Showing page 1 of 2